# Melanoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/melanoma

> 12 upcoming FDA catalysts in melanoma: fianlimab (REGN) on Jan to Apr 2027 (topline data readout); fianlimab (REGN) on January 2027 (primary completion); KISQALI® (ribociclib, NVS) on Feb to May 2027 (topline data readout); KISQALI® (ribociclib, NVS) on February 2027 (primary completion); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 4, 2025 | [RHUPH20 primary completion](https://sec-api.dev/pdufa/rhuph20) | BMY | Melanoma | completed | "NCT05625399 (A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05625399)) |
| February 2, 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | withdrawn | "NCT05926960 (A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05926960)) |
| March 12, 2026 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | completed | "NCT05352672 (Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05352672)) |
| August 26, 2026 | [RHUPH20 topline data readout](https://sec-api.dev/pdufa/rhuph20) | BMY | Melanoma | completed | "NCT05625399 (A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05625399?tab=results)) |
| Oct 2026 to Jan 2027 | [Encorafenib topline data readout](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | scheduled | "NCT04657991 (A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04657991)) |
| October 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | delayed | "NCT04657991 (A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04657991)) |
| Nov 2026 to Feb 2027 | [Libtayo® (cemiplimab) topline data readout](https://sec-api.dev/pdufa/cemiplimab) | REGN | Melanoma | scheduled | "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06190951)) |
| November 2026 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Melanoma | scheduled | "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06190951)) |
| Jan to Apr 2027 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608291)) |
| January 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608291)) |
| Feb to May 2027 | [KISQALI® (ribociclib) topline data readout](https://sec-api.dev/pdufa/ribociclib) | NVS | Melanoma | scheduled | "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04417621)) |
| February 2027 | [KISQALI® (ribociclib) primary completion](https://sec-api.dev/pdufa/ribociclib) | NVS | Melanoma | scheduled | "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04417621)) |
| Mar to Jun 2027 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246916)) |
| March 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246916)) |
| Jan to Apr 2028 | [ABP-206 topline data readout](https://sec-api.dev/pdufa/abp-206) | AMGN | Melanoma | scheduled | "NCT06054555 (A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054555)) |
| January 2028 | [ABP-206 primary completion](https://sec-api.dev/pdufa/abp-206) | AMGN | Melanoma | scheduled | "NCT06054555 (A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054555)) |
| Oct 2029 to Jan 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Melanoma | scheduled | "NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05933577)) |
| October 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Melanoma | scheduled | "NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05933577)) |
| Oct 2030 to Jan 2031 | [Fianlimab+cemiplimab topline data readout](https://sec-api.dev/pdufa/fianlimab-cemiplimab) | REGN | Melanoma | scheduled | "NCT06848088 (A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-10-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06848088)) |
| October 2030 | [Fianlimab+cemiplimab primary completion](https://sec-api.dev/pdufa/fianlimab-cemiplimab) | REGN | Melanoma | scheduled | "NCT06848088 (A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-10-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06848088)) |

## Drugs

- [RHUPH20](https://sec-api.dev/pdufa/rhuph20) (BMY)
- [Encorafenib](https://sec-api.dev/pdufa/encorafenib) (PFE)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [Libtayo® (cemiplimab)](https://sec-api.dev/pdufa/cemiplimab) (REGN)
- [KISQALI® (ribociclib)](https://sec-api.dev/pdufa/ribociclib) (NVS)
- [ABP-206](https://sec-api.dev/pdufa/abp-206) (AMGN)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Fianlimab+cemiplimab](https://sec-api.dev/pdufa/fianlimab-cemiplimab) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/melanoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Melanoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/melanoma

```bibtex
@misc{secapidev_indications_melanoma_20261116,
  title        = {Melanoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/melanoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_melanoma_20261116","title":"Melanoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/melanoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
